These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36461740)

  • 1. Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein.
    Lee L; Gollen R; Fathallah AM; Gao L; Patil S
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S95-S109. PubMed ID: 36461740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases.
    Ahmed MA; Burnham J; Dwivedi G; AbuAsal B
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):429-444. PubMed ID: 37140724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities.
    Abuasal B; Ahmed MA; Patel P; Albusaysi S; Sabarinath S; Uppoor R; Mehta M
    Clin Pharmacol Ther; 2022 Apr; 111(4):786-798. PubMed ID: 34860361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs.
    Kaspera R; Shitara Y
    AAPS J; 2024 Jun; 26(4):71. PubMed ID: 38886275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019-2023) by US FDA, best practices and recommendations.
    Mitra A; Lee JB; Steinbach D; Hazra A; Krishna R
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):475-493. PubMed ID: 37925369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs.
    An G
    J Clin Pharmacol; 2024 Jan; 64(1):45-57. PubMed ID: 37589246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases.
    Durairaj C; Bhattacharya I
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):445-459. PubMed ID: 37296230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases.
    Li RJ; Ma L; Li F; Li L; Bi Y; Yuan Y; Li Y; Xu Y; Zhang X; Liu J; Bhattaram VA; Wang J; Schuck R; Pacanowski M; Zhu H
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S27-S37. PubMed ID: 36461744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity Considerations for Therapeutic Modalities Used in Rare Diseases.
    Fathallah AM; Oldfield P; Fiedler-Kelly J; Ramadan A
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S110-S118. PubMed ID: 36461746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins.
    Wang YC; Ji P; Hariharan S; Wang J; Okusanya O; AbuAsal B; Zhu H; Madabushi R; Huang SM; Zineh I
    Clin Pharmacol Ther; 2024 Mar; 115(3):440-451. PubMed ID: 38235832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine Development.
    Desikan R; Germani M; van der Graaf PH; Magee M
    J Pharm Sci; 2024 Jan; 113(1):22-32. PubMed ID: 37924975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding studies in drug development for rare genetic diseases.
    Wang L; Wang J; Feng J; Doi M; Pepe S; Pacanowski M; Schuck RN
    Orphanet J Rare Dis; 2022 Apr; 17(1):156. PubMed ID: 35382851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases.
    Qosa H; Hassan HE; Younis IR
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S72-S78. PubMed ID: 36461747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case studies in rare disease small molecule discovery and development.
    Schmidt D; Thompson C
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127462. PubMed ID: 32791196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental Pharmacodynamics and Modeling in Pediatric Drug Development.
    Conklin LS; Hoffman EP; van den Anker J
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S87-S94. PubMed ID: 31502687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.